Novavax files COVID-19 vaccine data with FDA

Novavax on Friday filed final data with the Food and Drug Administration for its COVID-19 vaccine, clearing the way for a potential emergency approval next year.

The move was the last step for the Maryland-based biotechnology company to fulfill prerequisites for its protein-based vaccine, which is different than the other three vaccines approved in the U.S. from Pfizer, Moderna and Johnson & Johnson.